SCHEDULE 13G/A: Farallon Capital Amends Stake in Beam Therapeutics, Disclosing 9.99% Beneficial Ownership

Farallon Capital and its affiliated entities have filed an amended Schedule 13G, disclosing a collective beneficial ownership of 9.99% in Beam Therapeutics Inc. common stock, including shares and exercisable warrants.

Summary

• Farallon Capital and its affiliated funds and general partners (collectively, the "Reporting Persons") have filed an Amendment No. 4 to Schedule 13G regarding their beneficial ownership of Beam Therapeutics Inc. common stock.
• As of March 31, 2025, the Farallon Funds collectively hold 9,928,111 shares of Beam Therapeutics Inc. common stock.
• Additionally, the Farallon Funds hold 1,404,988 Common Stock Purchase Warrants.
• A Beneficial Ownership Limitation prevents the Reporting Persons from exercising warrants if it would result in ownership exceeding 9.99% of the outstanding shares.
• As of the report date, only 44,868 shares from the warrants are currently exercisable, with the remaining 1,360,120 warrants not exercisable due to this limitation.
• The aggregate beneficial ownership reported by the Farallon group, including shares and currently exercisable warrants, is 9,972,980 shares, representing 9.99% of the class.
• The Reporting Persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing beneficial ownership and does not contain information that inherently conveys positive or negative sentiment regarding the issuer's performance or prospects.

Risks

• The Beneficial Ownership Limitation restricts the full exercise of 1,360,120 warrants, preventing the Reporting Persons from increasing their stake beyond 9.99% through warrant exercise at this time.

Future Outlook

NA

Industry Context

This filing reflects a significant institutional investment firm's continued or adjusted stake in a biotechnology company, which is common in the highly capital-intensive and research-driven biotech sector where institutional backing is crucial.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity.

Key Dates

Keywords

Beam Therapeutics Inc., Farallon Capital, Schedule 13G, beneficial ownership, common stock, warrants, institutional investor, SEC filing, equity stake, investment fund